The NAFLD group presented higher BMI, systolic blood pressure (SBP), gamma-glutamyl transferase (GGT), total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, apolipoprotein-B, lipoprotein-A, fasting blood glucose, and uric acid but lower apolipoprotein-A1 levels than the no liver disease group (Table 1). The gene discussed is APOB; the disease is metabolic dysfunction-associated steatotic liver disease.